Abstract
Continuous blood purification (CBP) therapy, chiefly represented by continuous hemodiafiltration (CHDF), is performed mainly in the field of intensive care and is a vital component of acute blood purification therapy. In addition to renal indications, the scope of indications for CBP has been expanded to include non-renal conditions such as severe acute pancreatitis and liver failure. However, at present, hospitals carry out CBP on a trial and error basis. Here, we conducted the tenth questionnaire survey (2019) to investigate the current status of CBP in the Tokai and Hokuriku regions. The 30-item questionnaire included questions on the number of cases managed per year, type of membranes used, set up conditions, management during set up, activated clotting time, and clinical engineer duty system. A total of 83 facilities participated in the survey, including 69 in Tokai (Aichi, Gifu, Mie, and Shizuoka) and 14 in Hokuriku. It appears that many hospitals depend on the clinical engineer duty system for exchange of drug solutions, adjusting CBP conditions, and trouble-shooting issues in CBP management. Our findings suggest the importance of continued proactive involvement in the 24-h management system and in the standardization of CBP therapy.
